On Jan. 8, 2020, Xencor announced a technology license agreement in which Gilead Sciences will access Xencor’s Xtend extended half-life and Cytotoxic XmAb Fc technologies for developing and commercializing GS-9722, Gilead’s first-in-class effector-enhanced broadly neutralizing anti-HIV antibody, which is currently in Phase 1 clinical development.